Kezar Life Sciences: Mid-Term Growth Levers Heavily Discounted, Reduce To Hold

Nov. 16, 2022 1:23 AM ETKezar Life Sciences, Inc. (KZR)
Zach Bristow profile picture
Zach Bristow


  • Following a shift in market sentiment, I've narrowed my rating for Kezar Life Sciences from buy to hold.
  • The market has heavily discounted KZR's growth catalysts of clinical trial updates and regulatory tailwinds.
  • Market data also suggest a lack of buying support with long-term trends likely to continue.
  • Net-net, I rate KZR a hold on a $7.45 price target.

VR virtual reality goggles. 5G and Metaverse concept.


Investment Summary

The investment debate for Kezar Life Sciences, Inc. (NASDAQ:KZR) has changed drastically since my last rating on the company. Clinical trial and regulatory tailwinds were previous catalysts for KZR. However, the market has shifted to numbers and


Data: Upata


Data: KZR Q3 FY22 10-Q


Note: Red line = SPDR Portfolio S&P 500 Growth ETF; Blue line = SPDR Portfolio S&P 500 Value ETF. Both are benchmarked as proxies for the growth and value factors, respectively. (Data: Updata)


Data: KZR SEC Filings


Note: Fund ownership excludes ETFs due to cross ownership and indexing effect. (Data: Refinitiv Eikon, HB Insights)


Data: Updata


Data: Updata


Data: Updata


Data: Refinitiv Eikon

This article was written by

Zach Bristow profile picture
Buy side equity portfolio strategist serving mandates throughout EU/US/APAC. Helping you position your portfolios for the future is my top priority. Shoot me a message to discuss trade ides or talk portfolio construction. Disclaimer:The opinions expressed in all articles do not constitute as investment advice. Please remember to conduct your own due diligence.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.